Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this case report, a 65-year-old woman with non-small cell lung cancer experienced scarring alopecia with papulo-pustular lesions on the scalp due to gefitinib treatment, marking it as a rare instance of gefitinib-induced erosive pustular dermatosis of the scalp.

This report describes two cases of atypical Malassezia folliculitis in immunosuppressed patients, highlighting diagnostic challenges due to non-classical presentation in non-seborrheic areas.

This review discusses the adverse skin effects of EGFR inhibitors used in cancer treatment, exploring their mechanisms and offering strategies for prevention and management, but reports no new experimental findings.

In this original study, researchers documented 121 COVID-19 cases with a wide range of mucocutaneous manifestations, some linked to internal organ damage and others to new vaccine-associated dermatoses, emphasizing the importance of rapid diagnosis to prevent potentially life-threatening systemic events.

A rare skin reaction from cancer treatment was successfully managed with topical treatments and antihistamines.

This article discusses the classification of acne lesions and emphasizes the importance of evidence-based treatment and nursing care, without presenting new research results.

In this case study, a patient with moderate papulopustular acne showed improvement in acne scars and active lesions after three monthly treatments with autologous plasma-rich growth factors, which help regulate inflammation, inhibit bacterial growth, and restore collagen.

This study found that the monophasic oral contraceptive ethinylestradiol/chlormadinone acetate was more effective in treating mild to moderate papulopustular acne in women than ethinylestradiol/levonorgestrel.

This review discusses the cutaneous side effects of chemotherapy, noting that they frequently involve changes to skin, hair, and nails, and reports no new results.

This case study reports a unique and severe papulopustular eruption, likely induced by sorafenib treatment in a patient with metastatic renal cancer, which manifested as hyperkeratotic spicules and improved with cessation of the drug.

This study found that the combined oral contraceptive containing ethinyl estradiol and chlormadinone acetate was effective in reducing moderate papulopustular acne and other androgen-related skin disorders compared to placebo.

This review focuses on the various skin toxicities caused by chemotherapeutic and targeted tumor therapy drugs, including rashes, keratoacanthoma, and more severe conditions like Stevens-Johnson syndrome, without presenting new clinical results.

This review describes the dermatological uses of the contraceptive ethinylestradiol/chlormadinone acetate for conditions linked to high androgen levels and reports no new clinical results.

A skin condition called pyodermatitis vegetans was found in a patient with multiple myeloma for the first time.

This case report describes the improvement of papulo-pustular acne in a 27-year-old woman through individualized homoeopathic treatment with Kalium bromatum, placebo, and lifestyle advice, highlighting its potential usefulness in acne management.

Chemotherapy can cause skin side effects that affect patients' lives, but they can be managed to avoid interrupting cancer treatment.

In this reported case, a 50-year-old man developed an acneiform rash, a common skin side effect of EGFR inhibitor therapy, after starting lapatinib for breast cancer; treatment with doxycycline and hydrocortisone cream led to significant improvement within one week.

This review discusses azelaic acid's mechanisms and uses in dermatology, noting its effectiveness in treating conditions like rosacea, acne, and melasma, but reports no new clinical results.

This chapter reviews the skin side effects associated with targeted cancer therapies and emphasizes the importance of collaboration between oncologists and dermatologists without reporting new results.

This study reported that the most common skin side effect of epidermal growth factor receptor inhibitors was a papulopustular rash, treatable with symptom-targeted therapies, while drug suspension was rarely needed.

This review outlines dermatological toxicities associated with targeted cancer therapies and immunotherapies, emphasizing the need for collaborative management by oncologists and dermatologists but reports no new clinical findings.

This article discusses the range of skin-related side effects caused by chemotherapy and radiotherapy, including novel patterns emerging with targeted therapies, but does not report new clinical results.

This article reviews the current literature on rosacea, focusing on the new subtype classification system and the main theories of its pathogenesis, but reports no new clinical results.

In this study, demodicoses were found to be relatively common among immunocompetent patients, with a notable overlap with papulopustular rosacea.

This report verifies isotretinoin's significant efficacy in treating severe acne over the past year in the U.S., highlighting the need for careful patient selection and monitoring due to potential side effects.

This review discusses the skin side effects associated with targeted cancer therapies and reports no new clinical results; it emphasizes the need for empirical management based on expert opinion.

This review discusses the common dermatologic side effects of epidermal growth factor receptor inhibitors and provides practical guidance for recognizing and managing these effects; it reports no new clinical results.

This article reviews common skin reactions associated with epidermal growth factor receptor inhibitors and reports no new clinical findings, emphasizing the need for understanding nursing care and oncodermatology.

This study suggests that using a dermoscope, a handheld microscope, can effectively help distinguish between Pityrosporum folliculitis and Acne vulgaris by revealing unique lesion characteristics that are not visible to the naked eye, offering a practical diagnostic alternative when KOH examinations are unavailable.

This case report describes a patient who developed PRIDE syndrome-associated skin issues, including a pruritic papulopustular rash and alopecia, after starting treatment with the EGFR inhibitor erlotinib.